Fusidic acid
Fusidic acid is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fucidin | unapproved drug other | 2025-02-12 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06A: Antibiotics for topical use
— D06AX: Other antibiotics for topical use in atc
— D06AX01: Fusidic acid
— D09: Medicated dressings
— D09A: Medicated dressings
— D09AA: Medicated dressings with antiinfectives
— D09AA02: Fusidic acid
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01X: Other antibacterials in atc
— J01XC: Steroid antibacterials
— J01XC01: Fusidic acid
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA13: Fusidic acid
HCPCS
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic foot | D017719 | EFO_1001459 | — | 1 | — | 1 | 1 | — | 3 |
| Impetigo | D007169 | EFO_1000714 | L01 | — | — | 1 | 1 | 1 | 3 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | — | — | 1 | 1 | — | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | 1 | — | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | 1 | — | 1 |
| Blepharitis | D001762 | EFO_0009536 | H01.0 | — | — | — | 1 | — | 1 |
| Bacterial endocarditis | D004697 | EFO_1000830 | — | — | — | — | 1 | — | 1 |
| Endocarditis | D004696 | EFO_0000465 | I33 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 3 | 2 | — | 2 | 6 |
| Communicable diseases | D003141 | — | — | — | 2 | 2 | — | 2 | 5 |
| Infectious arthritis | D001170 | EFO_1001351 | M00 | — | 2 | 1 | — | 2 | 4 |
| Bacterial skin diseases | D017192 | — | — | — | 1 | 2 | — | — | 3 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | — | 1 | — | 1 | 2 |
| Eczema | D004485 | — | L30.9 | — | — | 1 | — | 1 | 2 |
| Dermatitis | D003872 | — | L30.9 | — | — | 1 | — | 1 | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | 1 | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | — | — | 1 | — | — | 1 |
| Bacterial infections | D001424 | — | A49 | — | — | 1 | — | — | 1 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Skin diseases | D012871 | — | L00-L99 | — | 1 | — | — | — | 1 |
| Fibrosis | D005355 | — | — | — | 1 | — | — | — | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 1 | — | — | — | 1 |
| Pulmonary fibrosis | D011658 | — | J84.10 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prosthesis-related infections | D016459 | EFO_1001406 | — | — | — | — | — | 2 | 2 |
| Staphylococcal infections | D013203 | — | A49.01 | — | — | — | — | 2 | 2 |
| Staphylococcus aureus | D013211 | NCBITaxon_1280 | — | — | — | — | — | 1 | 1 |
| Methicillin-resistant staphylococcus aureus | D055624 | — | — | — | — | — | — | 1 | 1 |
| Benign familial pemphigus | D016506 | — | Q82.8 | — | — | — | — | 1 | 1 |
| Psoriasis | D011565 | EFO_0000676 | L40 | — | — | — | — | 1 | 1 |
| Seborrheic keratosis | D017492 | EFO_0005584 | L82 | — | — | — | — | 1 | 1 |
| Keratosis | D007642 | — | — | — | — | — | — | 1 | 1 |
| Xanthomatosis | D014973 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Fusidic acid |
| INN | fusidic acid |
| Description | Fusidic acid is a steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum. It has a role as a protein synthesis inhibitor, an EC 2.7.1.33 (pantothenate kinase) inhibitor and an Escherichia coli metabolite. It is a 3alpha-hydroxy steroid, an 11alpha-hydroxy steroid, a sterol ester, a steroid acid, an alpha,beta-unsaturated monocarboxylic acid and a steroid antibiotic. It is a conjugate acid of a fusidate. It derives from a hydride of a 5alpha-cholestane. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)O[C@H]1C[C@@]2(C)[C@@H](C[C@@H](O)[C@H]3[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@@H]4CC[C@@]32C)/C1=C(\CCC=C(C)C)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 6990-06-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL374975 |
| ChEBI ID | 29013 |
| PubChem CID | 3000226 |
| DrugBank | DB02703 |
| UNII ID | 59XE10C19C (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,482 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
16,718 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use